---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-26-001208"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2026-09-02T00:41:15+00:00"
generated_at: "2026-09-02T10:05:05.417372+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Starling Oncology director Brad Hively to step down as Vice Chairman, not seek re-election

## Summary
- On Sept 1, 2026, Brad Hively notified Starling Oncology he will not stand for re-election at the 2027 annual meeting.
- Hively remains a director until the annual meeting but immediately relinquishes Vice Chairman and committee roles.
- Company states his decision is not due to any disagreement with operations, policies, or practices.
- No replacement named; board composition change effective at 2027 annual meeting.

## SEC filing metadata
- accession: 0001079973-26-001208
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2026-09-02T00:41:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001208/0001079973-26-001208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001208/stln_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-26-001208
- JSON: https://secwatch.observer/filing/0001079973-26-001208.json
- Plain text: https://secwatch.observer/filing/0001079973-26-001208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.